Literature DB >> 23114934

Nutritional status, systemic inflammation and prognosis of patients with gastrointestinal cancer.

K V Gomes de Lima1, R Maio.   

Abstract

INTRODUCTION: Systemic inflammatory response in individuals with cancer is related to a progressive reduction in total body mass, especially lean mass.
OBJECTIVE: The aim of the present study was to determine the association between nutritional status and systemic inflammatory response in patients with gastrointestinal cancer.
METHODOLOGY: A case series study was carried out involving 30 male and female adults and elderly patients with no prior treatment sent consecutively for surgery. Nutritional status was assessed using subjective and objective methods. Inflammatory response and prognosis were assessed through the determination of C-reactive protein (CRP), the Glasgow Prognostic Score and CRP/albumin ratio.
RESULTS: High prevalence values were found for systemic inflammation (73%), a greater risk of infectious and/or inflammatory complication (43%) and worse prognosis (50%). The percentage of weight loss was correlated with serum CRP (r = 0.38; p < 0.05) and the CRP/albumin ratio (r = 0.44; p < 0.05). Inflammation markers and prognosis were negatively correlated with serum albumin (r = -0.50; p < 0.05), body mass index (r = -0.39; p < 0.05) and total lymphocyte count (r = -0.37; p < 0.05). Patients with weight loss and malnourishment had significantly higher serum CRP and CRP/albumin ratio values as well as lower serum albumin levels in comparison to those without weight loss and in well-nourished.
CONCLUSION: Nutritional status is related to inflammation markers and prognosis in patients with gastrointestinal cancer. The diagnosis and attenuation of systemic inflammation should be part of the nutritional care of these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23114934     DOI: 10.3305/nh/2012.27.3.5567

Source DB:  PubMed          Journal:  Nutr Hosp        ISSN: 0212-1611            Impact factor:   1.057


  6 in total

1.  Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection.

Authors:  Ryuma Tokunaga; Yasuo Sakamoto; Shigeki Nakagawa; Daisuke Izumi; Keisuke Kosumi; Katsunobu Taki; Takaaki Higashi; Tatsunori Miyata; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2017-02-17       Impact factor: 3.402

2.  Scoring of prognostic parameters in patients with unresectable advanced or recurrent colorectal cancer undergoing chemotherapy.

Authors:  Masahide Ikeguchi; Ryugo Shimoda; Manabu Yamamoto; Yoshihiko Maeta; Keigo Ashida; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2013-09-11       Impact factor: 1.641

3.  The prognostic value of preoperative inflammation-based prognostic scores and nutritional status for overall survival in resected patients with nonmetastatic Siewert type II/III adenocarcinoma of esophagogastric junction.

Authors:  Lixiang Zhang; Yezhou Su; Zhangming Chen; Zhijian Wei; Wenxiu Han; Aman Xu
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

4.  A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma.

Authors:  Li-Xiang Zhang; Lei Chen; A-Man Xu
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

5.  Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Zhi-Jian Wei; Ya-Ting Qiao; Bai-Chuan Zhou; Abigail N Rankine; Li-Xiang Zhang; Ye-Zhou Su; A-Man Xu; Wen-Xiu Han; Pan-Quan Luo
Journal:  World J Gastrointest Surg       Date:  2022-08-27

6.  Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer.

Authors:  Weiwei Zhang; Kejun Liu; Bin Ye; Weijiang Liang; Yazhou Ren
Journal:  Cancer Med       Date:  2017-11-28       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.